Liver Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017 - Product Image

Liver Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017

  • ID: 4370714
  • Drug Pipelines
  • 136 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Abbott Diagnostics
  • Abcodia Ltd
  • AXO Science SAS
  • BioMark Technologies Inc
  • Bioprognos SL
  • China Sky One Medical Inc
  • MORE
Liver Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017

Summary

The Medical Devices sector report, “Liver Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017" provides an overview of Liver Cancer Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Liver Cancer Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by a team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Liver Cancer Diagnostic Tests under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Liver Cancer Diagnostic Tests and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry
Reasons to Buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Liver Cancer Diagnostic Tests under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbott Diagnostics
  • Abcodia Ltd
  • AXO Science SAS
  • BioMark Technologies Inc
  • Bioprognos SL
  • China Sky One Medical Inc
  • MORE
1.1 List of Tables
1.2 List of Figures

2. Introduction
2.1 Liver Cancer Diagnostic Tests Overview

3. Products under Development
3.1 Liver Cancer Diagnostic Tests - Pipeline Products by Stage of Development
3.2 Liver Cancer Diagnostic Tests - Pipeline Products by Territory
3.3 Liver Cancer Diagnostic Tests - Pipeline Products by Regulatory Path
3.4 Liver Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date

4. Liver Cancer Diagnostic Tests - Pipeline Products under Development by Companies
4.1 Liver Cancer Diagnostic Tests Companies - Pipeline Products by Stage of Development
4.2 Liver Cancer Diagnostic Tests - Pipeline Products by Stage of Development

5. Liver Cancer Diagnostic Tests Companies and Product Overview
5.1 Abbott Diagnostics Company Overview
5.1.1 Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview
5.2 Abcodia Ltd Company Overview
5.2.1 Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.3 AXO Science SAS Company Overview
5.3.1 AXO Science SAS Pipeline Products & Ongoing Clinical Trials Overview
5.4 BioMark Technologies Inc Company Overview
5.4.1 BioMark Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
5.5 Bioprognos SL Company Overview
5.5.1 Bioprognos SL Pipeline Products & Ongoing Clinical Trials Overview
5.6 China Sky One Medical Inc Company Overview
5.6.1 China Sky One Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
5.7 Digna Biotech SL Company Overview
5.7.1 Digna Biotech SL Pipeline Products & Ongoing Clinical Trials Overview
5.8 Drexel University Company Overview
5.8.1 Drexel University Pipeline Products & Ongoing Clinical Trials Overview
5.9 Exact Sciences Corp Company Overview
5.9.1 Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview
5.10 German Cancer Research Center Company Overview
5.10.1 German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview
5.11 Glycotest Inc Company Overview
5.11.1 Glycotest Inc Pipeline Products & Ongoing Clinical Trials Overview
5.12 ImCare Biotech LLC Company Overview
5.12.1 ImCare Biotech LLC Pipeline Products & Ongoing Clinical Trials Overview
5.13 Imperial College London Company Overview
5.13.1 Imperial College London Pipeline Products & Ongoing Clinical Trials Overview
5.14 IntegraGen SA Company Overview
5.14.1 IntegraGen SA Pipeline Products & Ongoing Clinical Trials Overview
5.15 Matrix-Bio, Inc. Company Overview
5.15.1 Matrix-Bio, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.16 NanoString Technologies Inc Company Overview
5.16.1 NanoString Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
5.17 National Cancer Institute US Company Overview
5.17.1 National Cancer Institute US Pipeline Products & Ongoing Clinical Trials Overview
5.18 Oncimmune (USA) LLC Company Overview
5.18.1 Oncimmune (USA) LLC Pipeline Products & Ongoing Clinical Trials Overview
5.19 Orion Genomics LLC Company Overview
5.19.1 Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview
5.20 PleX Diagnostics Inc (Inactive) Company Overview
5.20.1 PleX Diagnostics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
5.21 ProMIS Neurosciences Inc Company Overview
5.21.1 ProMIS Neurosciences Inc Pipeline Products & Ongoing Clinical Trials Overview
5.22 Proplex Technologies Llc Company Overview
5.22.1 Proplex Technologies Llc Pipeline Products & Ongoing Clinical Trials Overview
5.23 Proteome Sciences Plc Company Overview
5.23.1 Proteome Sciences Plc Pipeline Products & Ongoing Clinical Trials Overview
5.24 Roche Diagnostics International Ltd Company Overview
5.24.1 Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.25 University of Rochester Company Overview
5.25.1 University of Rochester Pipeline Products & Ongoing Clinical Trials Overview
5.26 Ventana Medical Systems Inc Company Overview
5.26.1 Ventana Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview
5.27 Viomics Inc. Company Overview
5.27.1 Viomics Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.28 XEPTAGEN SpA Company Overview
5.28.1 XEPTAGEN SpA Pipeline Products & Ongoing Clinical Trials Overview
5.29 Xiamen Zeesan Biotech Co.,Ltd Company Overview
5.29.1 Xiamen Zeesan Biotech Co.,Ltd Pipeline Products & Ongoing Clinical Trials Overview

6. Liver Cancer Diagnostic Tests - Recent Developments
6.1 Jul 25, 2017: Proteome Sciences: Interim Results for the Six Months Ended 30 June 2017
6.2 Jul 11, 2017: Integragen Reports Continued Growth During 1st Half Of 2017
6.3 Jul 10, 2017: Trovagene Regains Compliance with NASDAQ Listing Requirements
6.4 Jul 10, 2017: ProMIS Neurosciences Provides Second Quarter Update for 2017
6.5 Jun 28, 2017: Pfizer breaks ground on new R&D facility in Missouri
6.6 Jun 27, 2017: Pfizer Breaks Ground on New R&D Facility in Chesterfield, Missouri
6.7 Jun 12, 2017: Proteome Sciences: New Registered Address
6.8 Jun 06, 2017: ProMIS Neurosciences Appoints William C. Mobley to Scientific Advisory Board
6.9 May 10, 2017: Trovagene Announces First Quarter 2017 Company Highlights and Financial Results
6.10 May 10, 2017: NanoString Appoints Elisha W. Finney to Board of Directors
6.11 May 09, 2017: ProMIS Neurosciences Announces Q1 2017 Quarterly Results
6.12 May 04, 2017: PerkinElmer Announces Financial Results for the First Quarter of 2017
6.13 May 04, 2017: NanoString Technologies Releases Operating Results for First Quarter of 2017
6.14 May 03, 2017: Blueprint Medicines Reports First Quarter 2017 Financial Results
6.15 May 02, 2017: Pfizer Reports First-Quarter 2017 Results
6.16 Apr 21, 2017: IntegraGen Announces 2016 Annual Results: Increase in operating revenues and significant improvement in operating income (+22%)
6.17 Apr 13, 2017: Trovagene Announces the Addition of Dr. Sandra Silberman to its Clinical Advisory Board
6.18 Apr 03, 2017: Proteome Sciences Announces Appointment of Richard Dennis as Chief Commercial Officer
6.19 Mar 30, 2017: ProMIS Neurosciences announces overview of first quarter 2017 progress and outlook for near term value creation
6.20 Mar 28, 2017: Proteome Sciences Announces Preliminary results for the year ended 31 December 2016 Notice of AGM
6.21 Mar 23, 2017: PerkinElmer to Display Portfolio of Cancer Research Technologies and Workflow Solutions at 2017 AACR Annual Meeting
6.22 Mar 22, 2017: ProMIS Neurosciences Announces Appointment of Daniel Geffken as Chief Financial Officer
6.23 Mar 15, 2017: Trovagene Reports Fourth Quarter and Year End 2016 Financial Results
6.24 Mar 15, 2017: ProMIS Neurosciences Announces Fiscal 2016 Annual Results
6.25 Mar 09, 2017: Blueprint Medicines Reports Fourth Quarter and Full Year 2016 Financial Results
6.26 Mar 02, 2017: ProMIS Neurosciences announces appointment of Anthony Giovinazzo to its Board of Directors
6.27 Mar 01, 2017: NanoString Technologies Releases Fourth Quarter and Full Year 2016 Operating Results and Provides 2017 Outlook
6.28 Feb 27, 2017: The Novartis Institutes for BioMedical Research and NanoString Technologies Demonstrates at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium
6.29 Feb 23, 2017: Ronald E. Blaylock Elected to Pfizer’s Board of Directors
6.30 Feb 02, 2017: PerkinElmer Announces Financial Results for Fourth Quarter and Full Year 2016
6.31 Jan 31, 2017: Pfizer Reports Fourth-Quarter And Full-Year 2016 Results
6.32 Jan 10, 2017: NanoString Technologies Provides Preliminary Operational and Financial Results for 2016
6.33 Jan 09, 2017: IntegraGen Reports Sharp Increase in Sales During 2016
6.34 Nov 21, 2016: Anthony J. Maddaluna, Executive Vice President and President of Pfizer Global Supply to Retire
6.35 Nov 14, 2016: Blueprint Medicines Announces Appointment of Marion Dorsch, Ph.D. as Chief Scientific Officer and the Transition of Christoph Lengauer, Ph.D., MBA, to a Newly Created Executive Vice President Role
6.36 Nov 10, 2016: Blueprint Medicines Reports Third Quarter 2016 Financial Results
6.37 Nov 09, 2016: Trovagene Reports Third Quarter 2016 Financial Results and Accomplishments
6.38 Nov 07, 2016: PerkinElmer Announces Financial Results for the Third Quarter of 2016
6.39 Nov 02, 2016: ProMIS Neurosciences Announces Third Quarter 2016 Results
6.40 Nov 02, 2016: NanoString Technologies Releases Operating Results for Third Quarter of 2016
6.41 Nov 01, 2016: Pfizer Reports Third-Quarter 2016 Results
6.42 Oct 18, 2016: ProMIS Neurosciences announces appointment of Dr. Richard Gregory to its Board of Directors
6.43 Oct 17, 2016: PerkinElmer Elects Samuel Chapin to Board of Directors
6.44 Oct 14, 2016: IntegraGen Reports Revenues for First Half of 2016
6.45 Sep 26, 2016: Pfizer Decides Remaining One Company Best Positions Company To Maximize Future Value Creation
6.46 Sep 26, 2016: PerkinElmer Announces New Organizational Structure
6.47 Sep 15, 2016: Proteome Sciences: Interim Results
6.48 Sep 07, 2016: Pfizer Appoints Chief Scientific Officer for Neuroscience Research
6.49 Sep 06, 2016: Blueprint Medicines Announces Appointment of Tracey McCain as Chief Legal Officer and Executive Vice President
6.50 Aug 12, 2016: ProMIS Neurosciences Announces Second Quarter 2016 Results
6.51 Aug 09, 2016: Blueprint Medicines Reports Second Quarter 2016 Financial Results

7. Appendix
7.1 Methodology
7.2 About
7.3 Contact Us
7.4 Disclaimer

1.1 List of Tables
Table 1: Liver Cancer Diagnostic Tests - Pipeline Products by Stage of Development
Table 2: Liver Cancer Diagnostic Tests - Pipeline Products by Territory
Table 3: Liver Cancer Diagnostic Tests - Pipeline Products by Regulatory Path
Table 4: Liver Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date
Table 5: Liver Cancer Diagnostic Tests Companies - Pipeline Products by Stage of Development
Table 6: Liver Cancer Diagnostic Tests - Pipeline Products by Stage of Development
Table 7: Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview
Table 8: ARCHITECT c16000 System - PIVKA Assay - Product Status
Table 9: ARCHITECT c16000 System - PIVKA Assay - Product Description
Table 10: ARCHITECT c4000 System - PIVKA Assay - Product Status
Table 11: ARCHITECT c4000 System - PIVKA Assay - Product Description
Table 12: ARCHITECT c8000 System - PIVKA Assay - Product Status
Table 13: ARCHITECT c8000 System - PIVKA Assay - Product Description
Table 14: ARCHITECT ci16200 Integrated System - PIVKA Assay - Product Status
Table 15: ARCHITECT ci16200 Integrated System - PIVKA Assay - Product Description
Table 16: ARCHITECT ci4100 Integrated System - PIVKA Assay - Product Status
Table 17: ARCHITECT ci4100 Integrated System - PIVKA Assay - Product Description
Table 18: ARCHITECT ci8200 Integrated System - PIVKA Assay - Product Status
Table 19: ARCHITECT ci8200 Integrated System - PIVKA Assay - Product Description
Table 20: Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 21: Biomarker Test - Liver Cancer - Product Status
Table 22: Biomarker Test - Liver Cancer - Product Description
Table 23: AXO Science SAS Pipeline Products & Ongoing Clinical Trials Overview
Table 24: Multiplexed Detection - Des-Carboxy Prothrombin - Product Status
Table 25: Multiplexed Detection - Des-Carboxy Prothrombin - Product Description
Table 26: Multiplexed Detection - Matrix metalloproteinase 1 - Product Status
Table 27: Multiplexed Detection - Matrix metalloproteinase 1 - Product Description
Table 28: Multiplexed Detection - Procollagen type III N-terminal peptide - Product Status
Table 29: Multiplexed Detection - Procollagen type III N-terminal peptide - Product Description
Table 30: BioMark Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 31: Biomarker Assay - Hepatocellular Cancer - Product Status
Table 32: Biomarker Assay - Hepatocellular Cancer - Product Description
Table 33: Bioprognos SL Pipeline Products & Ongoing Clinical Trials Overview
Table 34: MBDAA Liver Cancer Test - Product Status
Table 35: MBDAA Liver Cancer Test - Product Description
Table 36: China Sky One Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 37: Diagnostic Kit - Liver Cancer - Product Status
Table 38: Diagnostic Kit - Liver Cancer - Product Description
Table 39: Digna Biotech SL Pipeline Products & Ongoing Clinical Trials Overview
Table 40: HCC Molecular Marker Assay - Product Status
Table 41: HCC Molecular Marker Assay - Product Description
Table 42: Oxidated APO-A1 Assay - Product Status
Table 43: Oxidated APO-A1 Assay - Product Description
Table 44: Drexel University Pipeline Products & Ongoing Clinical Trials Overview
Table 45: Diagnostic Test - Liver Cancer - Product Status
Table 46: Diagnostic Test - Liver Cancer - Product Description
Table 47: Glycan-Based Biomarker Assay - Liver Cancer - Product Status
Table 48: Glycan-Based Biomarker Assay - Liver Cancer - Product Description
Table 49: Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 50: Blood-based Liver Cancer Test - Product Status
Table 51: Blood-based Liver Cancer Test - Product Description
Table 52: German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview
Table 53: RAGE Based Diagnostic Assay - Liver Cancer - Product Status
Table 54: RAGE Based Diagnostic Assay - Liver Cancer - Product Description
Table 55: Glycotest Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 56: HCC Panel - Product Status
Table 57: HCC Panel - Product Description
Table 58: ImCare Biotech LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 59: HepatoDetect Diagnostic Kit - Product Status
Table 60: HepatoDetect Diagnostic Kit - Product Description
Table 61: Imperial College London Pipeline Products & Ongoing Clinical Trials Overview
Table 62: Diagnostic Assay - HCC - Product Status
Table 63: Diagnostic Assay - HCC - Product Description
Table 64: IntegraGen SA Pipeline Products & Ongoing Clinical Trials Overview
Table 65: Diagnostic Test - Hepatocellular Carcinoma - Product Status
Table 66: Diagnostic Test - Hepatocellular Carcinoma - Product Description
Table 67: Matrix-Bio, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 68: VeraMarker LCS (Liver Cancer Screening) Test - Product Status
Table 69: VeraMarker LCS (Liver Cancer Screening) Test - Product Description
Table 70: VeraMarker Liver Cancer Screening Test - Hepatitis - Product Status
Table 71: VeraMarker Liver Cancer Screening Test - Hepatitis - Product Description
Table 72: NanoString Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 73: In Vitro Diagnostic Assay - HCC Gene Signature - Product Status
Table 74: In Vitro Diagnostic Assay - HCC Gene Signature - Product Description
Table 75: National Cancer Institute US Pipeline Products & Ongoing Clinical Trials Overview
Table 76: HCC Gene Signature Diagnostic Test - Product Status
Table 77: HCC Gene Signature Diagnostic Test - Product Description
Table 78: HCC Gene Signature Prognostic Test - Product Status
Table 79: HCC Gene Signature Prognostic Test - Product Description
Table 80: Oncimmune (USA) LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 81: EarlyCDT - Liver Cancer - Product Status
Table 82: EarlyCDT - Liver Cancer - Product Description
Table 83: Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 84: Diagnostic Assay - Liver Cancer - Product Status
Table 85: Diagnostic Assay - Liver Cancer - Product Description
Table 86: PleX Diagnostics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
Table 87: HCCpleX - Product Status
Table 88: HCCpleX - Product Description
Table 89: ProMIS Neurosciences Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 90: Screening Test - Liver Cancer - Product Status
Table 91: Screening Test - Liver Cancer - Product Description
Table 92: Proplex Technologies Llc Pipeline Products & Ongoing Clinical Trials Overview
Table 93: Biomarker Diagnostic Test - Liver Cancer - Product Status
Table 94: Biomarker Diagnostic Test - Liver Cancer - Product Description
Table 95: Proteome Sciences Plc Pipeline Products & Ongoing Clinical Trials Overview
Table 96: Biomarker Assay - Liver Cancer - Product Status
Table 97: Biomarker Assay - Liver Cancer - Product Description
Table 98: Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 99: Cobas 8000 Analyzer Series With e 801 Module - PIVKA Assay - Product Status
Table 100: Cobas 8000 Analyzer Series With e 801 Module - PIVKA Assay - Product Description
Table 101: Glypican-3 MAb Companion Diagnostic Test - Product Status
Table 102: Glypican-3 MAb Companion Diagnostic Test - Product Description
Table 103: University of Rochester Pipeline Products & Ongoing Clinical Trials Overview
Table 104: Biomarker Test - HCC - Product Status
Table 105: Biomarker Test - HCC - Product Description
Table 106: Ventana Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 107: BLU-554 Companion Diagnostic Assay - Hepatocellular Carcinoma - Product Status
Table 108: BLU-554 Companion Diagnostic Assay - Hepatocellular Carcinoma - Product Description
Table 109: Viomics Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 110: Diagnostic Assay - Liver Cancer - Product Status
Table 111: Diagnostic Assay - Liver Cancer - Product Description
Table 112: XEPTAGEN SpA Pipeline Products & Ongoing Clinical Trials Overview
Table 113: compleXima HCC Biochip - Liver Cancer - Product Status
Table 114: compleXima HCC Biochip - Liver Cancer - Product Description
Table 115: DCP-IgM Kit - Liver Cancer - Product Status
Table 116: DCP-IgM Kit - Liver Cancer - Product Description
Table 117: GPC3-IgM Kit - Liver Cancer - Product Status
Table 118: GPC3-IgM Kit - Liver Cancer - Product Description
Table 119: Osteopontin-IgM Kit - Liver Cancer - Product Status
Table 120: Osteopontin-IgM Kit - Liver Cancer - Product Description
Table 121: Survivin-IgM Kit - Liver Cancer - Product Status
Table 122: Survivin-IgM Kit - Liver Cancer - Product Description
Table 123: VEGF-IgM Kit - Liver Cancer - Product Status
Table 124: VEGF-IgM Kit - Liver Cancer - Product Description
Table 125: Xiamen Zeesan Biotech Co.,Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 126: Theranostic - Liver Cancer Metastasis - Product Status
Table 127: Theranostic - Liver Cancer Metastasis - Product Description
Table 128: Glossary

1.2 List of Figures
Figure 1: Liver Cancer Diagnostic Tests - Pipeline Products by Stage of Development
Figure 2: Liver Cancer Diagnostic Tests - Pipeline Products by Territory
Figure 3: Liver Cancer Diagnostic Tests - Pipeline Products by Regulatory Path
Figure 4: Liver Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Abbott Diagnostics
  • Abcodia Ltd
  • AXO Science SAS
  • BioMark Technologies Inc
  • Bioprognos SL
  • China Sky One Medical Inc
  • Digna Biotech SL
  • Drexel University
  • Exact Sciences Corp
  • German Cancer Research Center
  • Glycotest Inc
  • ImCare
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll